Real-World Persistence and Time to Next Treatment with Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-H élène Lafeuille, Patrick Lefebvre, Qing Huang, Michael Choi Tags: Original Study Source Type: research